The research applies to a class of drugs called Glucagon-like peptide 1 receptor agonists (GLP1-RAs)
Human coronaviruses (HCoVs) have only recently been shown to cause both lower and upper respiratory tract infections
Many benign dendritic melanocytes with pigment-laden dendritic processes were distributed in the epithelium
[DOI] [PMC free article] [PubMed] [Google Scholar] 194.Qeadan F., McCunn A., Tingey B
This is a once-weekly subcutaneous injection that affects GIP (glucose-dependent insulinotrophic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, both appetite hormones
When to contact your GP, diabetes team, or healthcare professional: Severe or persistent nausea and vomiting preventing adequate fluid or food intake Signs of dehydration (dark urine, dizziness, reduced urination) Severe abdominal pain, particularly if accompanied by vomiting, or right upper abdominal pain with fever Symptoms of hypoglycaemia that don't resolve with usual treatment Unexplained weight loss exceeding clinical targets Changes in mood or suicidal thoughts Any concerns about medication tolerance or effectiveness The MHRA continues to monitor the safety profile of incretin medications through the Yellow Card scheme